Transforming growth factor-β1 inhibits expression of selenoprotein P in cultured human liver cells  by Mostert, Volker et al.
Transforming growth factor-L1 inhibits expression of selenoprotein P in
cultured human liver cells
Volker Mosterta, Ingeborg Dreherb, Josef Ko«hrleb, Josef Abela;*
aMedical Institute of Environmental Hygiene at the Heinrich-Heine-Universita«t Du«sseldorf, Department of Experimental Toxicology,
Auf’m Hennekamp 50, 40225 Du«sseldorf, Germany
bKlinische Forschergruppe, Medizinische Poliklinik, Universita«t Wu«rzburg, Ro«ntgenring 11, 97070 Wu«rzburg, Germany
Received 6 September 1999
Abstract The effect of cytokines on the expression of
selenoprotein P (SeP) in the human liver cell line HepG2 was
investigated. Treatment with interleukin-1L, interferon-Q, and
tumor necrosis factor-K had no effect on SeP levels in culture
media or on SeP mRNA expression. Conversely, Western
analysis revealed a dose-dependent reduction of SeP content in
culture medium after treatment with transforming growth factor
(TGF)-L1 with an IC50 of 31 pM. Treatment with 100 pM TGF-
L1 for 48 h led to a decrease to 21 þ 9% of controls. RT-PCR
analysis of SeP mRNA expression demonstrated an inhibition of
SeP transcription to 40 þ 2% of control levels after 24 h. The
expression of a luciferase reporter construct under control of the
human SeP promoter was downregulated by TGF-L1 treatment
in a dose-dependent fashion indicating a transcriptional regula-
tion of the SeP gene by TGF-L1.
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1. Introduction
Selenoprotein P (SeP) is a selenocysteine-containing protein
that accounts for about 50% of total plasma selenium in hu-
mans [1]. It di¡ers from all other mammalian selenoproteins
identi¢ed so far by its high selenium content. The mRNA of
human SeP predicts the occurrence of selenocysteine at 10
positions [2] whereas other selenoproteins contain only one
selenocysteine residue per subunit. The physiological function
of SeP is not completely understood, but a role as a part of
the body’s antioxidant defense line seems most likely. In rat
and human plasma, several isoforms of SeP were detected
[3^5]. Human plasma contains at least two distinct isoforms
with di¡erent selenium contents and molecular masses of
61 and 51 kDa, respectively [6].
Recently, a role of SeP in human plasma as a protective
agent against the oxidation and nitration reactions mediated
by peroxynitrite, a potent oxidant generated in vivo, was dem-
onstrated [7].
Additionally, the 5P-£anking region of the human SeP gene
was shown to contain interferon-Q (IFN-Q) responsive ele-
ments and a negative regulation of the SeP promoter by
pro-in£ammatory cytokines such as interleukin (IL)-1L and
tumor necrosis factor-K (TNF-K) was found [8]. In this study,
we investigated whether cytokines like IL-1L, IFN-Q, TNF-K,
or transforming growth factor (TGF)-L1 regulate the expres-
sion of SeP.
2. Materials and methods
2.1. Materials
Recombinant human IL-1L, IFN-Q, and TNF-K were from Cyto-
gen. Recombinant human TGF-L1, sodium selenite, ammonium ace-
tate, TRIreagent total RNA isolation kit, phenylmethylsulfonyl £uo-
ride (PMSF), cycloheximide (CHX), and actinomycin D (ActD) were
supplied by Sigma (Taufkirchen, Germany). RPMI 1640 medium was
from PAA (Linz, Austria), penicillin/streptomycin, basal medium sup-
plement (BMS), fetal calf serum (FCS), sodium hydrogen carbonate,
and L-glutamine were purchased from Seromed (Berlin, Germany).
2.2. Cell culture and treatment
The human hepatocarcinoma line HepG2 was cultured in RPMI
1640 medium containing 10% FCS, 1% penicillin/streptomycin, 1 mg/
ml L-glutamine, and 0.15% NaHCO3. Cells were maintained under
standard conditions at 37‡C in 5% CO2. Forty-eight hours before
treatment, cells were cultured in RPMI 1640 medium containing 5%
BMS, 1% penicillin/streptomycin, 1 mg/ml L-glutamine, and 0.15%
NaHCO3. Cells were then treated as indicated. During treatment,
250 nM sodium selenite was present in media to allow selenoprotein
synthesis.
2.3. Enrichment of selenoprotein P from culture media
To 15 ml of culture medium, PMSF was added to give a ¢nal
concentration of 1 mM. Samples of 10 ml were applied to a 1 ml
HiTrap heparin agarose column (Pharmacia). The column was
washed with 10 volumes of ice-cold wash bu¡er (100 mM ammonium
acetate, 50 mM Tris-HCl, pH 7.4), and the SeP-containing fraction
was eluted with wash bu¡er containing 2 M ammonium acetate. One
milliliter of the eluate was collected for Western analysis.
2.4. Western blotting
Western detection of SeP was performed as described previously
using a⁄nity-puri¢ed anti-SeP IgG [6].
2.5. RT-PCR
RT-PCR analysis of mRNA expression was performed as described
elsewhere [9]. Primer sequences and PCR conditions are given in Ta-
ble 1.
Transcripts with common PCR conditions (SeP/GAPDH, extracel-
lular/phospholipid hydroperoxide glutathione peroxidase (GPX3/
GPX4)) were coampli¢ed.
2.6. Plasmids and cell culture for transfection
The 1800 bp BglII/KpnI SeP promoter fragment was isolated from
the plasmid pBK15 [8] and subcloned into the luciferase reporter gene
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plasmid pGL3basic revealing plasmid BK4GL3. Transfection was per-
formed as described previously [8]. After 24 h, the transfection solu-
tion was replaced by DMEM-F12 medium containing 250 nM sodium
selenite (controls) and human recombinant TGF-L1 (0.1^100 pM).
After a further incubation period of 16 h, the cells were harvested
and luciferase and L-galactosidase activity was determined as de-
scribed before [8].
2.7. Data analysis
Bands from Western blots and RT-PCR were scanned with an
OmniMedia Scanner and quanti¢ed with Whole Band Analyzer soft-
ware (Millipore, Uº berlingen, Germany). Curve ¢tting and statistical
analysis (Student’s t-test) were done by GraphPad Prism software
(GraphPad Software, San Diego, CA, USA).
3. Results
3.1. E¡ect of pro-in£ammatory cytokines on SeP expression
Treatment of HepG2 cells with IL-1L (50 ng/ml), IFN-Q
(100 ng/ml), and TNF-K (50 ng/ml) for 2, 8, 16, or 24 h
revealed no e¡ect either on SeP secretion or on SeP mRNA
expression (data not shown).
3.2. Dose-dependent inhibition of SeP secretion by TGF-L1
When HepG2 cells were incubated for 48 h with di¡erent
doses of TGF-L1, levels of SeP in culture medium were mark-
edly decreased in a dose-dependent fashion as detected by
Western analysis (Fig. 1). The half-maximal inhibitory con-
centration (IC50) was about 30 pM. Treatment with 100 pM
TGF-L1 reduced the SeP concentration to 21 þ 9% (mean þ
S.E.M., n = 3) of controls.
3.3. E¡ect of TGF-L1 on SeP, GPX3, and GPX4 expression
HepG2 cells were incubated with 100 pM TGF-L1 for 2, 8,
16, or 24 h. After 24 h, a maximum reduction of SeP mRNA
levels to 40 þ 2% (n = 3) of the respective control was observed
(Fig. 2). TGF-L1 had no e¡ect on GPX3 and GPX4 mRNA
expression in HepG2 cells.
3.4. E¡ect of protein synthesis inhibitor CHX on
TGF-L1-mediated mRNA decrease
To characterize the mechanism of TGF-L1 action on SeP
expression, cells were coincubated with 35 WM CHX and 100
pM TGF-L1 for 16 h. The presence of CHX neutralizes the
inhibitory e¡ect of TGF-L1 on SeP mRNA expression (data
not shown).
3.5. In£uence of TGF-L1 on SeP mRNA stability
To examine whether TGF-L1 in£uences SeP mRNA stabil-
ity, experiments with ActD, an inhibitor of mRNA synthesis,
were performed. Cells were ¢rst treated simultaneously with
100 pM TGF-L1 and 5 Wg/ml ActD for 6 and 16 h. The
inhibitory e¡ect of TGF-L1 was counteracted by this treat-
ment (Fig. 3, top, lanes 1^5), indicating that mRNA synthesis
is required for negative regulation of SeP mRNA. Densito-
metric analysis of band intensities revealed no di¡erence in
SeP-mRNA abundance between TGF-L1 treated and control
cells in presence of ActD (Fig. 3, bottom).
When cells were treated for 3 h with 100 pM TGF-L1 prior
to addition of ActD, the inhibitory e¡ect of TGF-L1 was
Fig. 1. In£uence of TGF-L1 on secretion of SeP by HepG2 cells.
Top: Result of a Western blot. Bottom: Dose-e¡ect relationship for
SeP61.
Fig. 2. Time course of SeP mRNA expression in HepG2 cells after
treatment with 100 pM TGF-L1. Top: Result of a typical RT-PCR.
Bottom: Band intensities representing SeP mRNA expression nor-
malized to the respective untreated controls are given (n = 3,
mean þ S.E.M.). Signi¢cant (P6 0.05) di¡erences to controls are in-
dicated by an asterisk.
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restored (Fig. 3, top, lanes 6^11). These results indicate that
enhanced mRNA degradation is unlikely to be responsible for
the e¡ect of TGF-L1 on SeP expression.
3.6. TGF-L1 modulates SeP promoter activity
To further characterize the transcriptional e¡ect of TGF-L1
on SeP expression, reporter gene assays under control of the
human SeP promoter were conducted. As shown in Fig. 4,
TGF-L1 treatment of HepG2 cells that were transfected with
the SeP promoter construct BK4GL3 resulted in a marked
dose-dependent decrease of luciferase activity. Treatment
with 100 pM TGF-L1 for 8 h reduced normalized SeP-pro-
moter activity to 49.4 þ 3.2% of controls (mean þ S.E.M.,
n = 10^12, data not shown), 16 h treatment reduced normal-
ized SeP promoter activity to 35.2 þ 1.6% (mean þ S.E.M.,
n = 10^12). In contrast, background luciferase activity of the
pGL3 basic plasmid was not in£uenced by TGF-L1 thus in-
dicating a speci¢c inhibition of SeP promoter activity by
TGF-L1 treatment.
4. Discussion
Up to now, SeP secretion by human liver cells was known
to be regulated by selenium supply only [10]. In the present
study, we show that TGF-L1 exerts an inhibitory e¡ect on SeP
secretion as well as on SeP mRNA abundance via negative
regulation of the SeP promoter.
TGF-L1 produces a variety of e¡ects in a number of tissues
and cell lines. TGF-L1-de¢cient mice show multifocal in£am-
matory responses and tissue necrosis leading to fatal organ
failure which suggests a central role of TGF-L1 in the regu-
lation of in£ammatory reactions [11,12]. During in£amma-
tion, TGF-L1 is responsible for the induction of extracellular
matrix proteins [13] and for inhibition of lymphocyte prolif-
eration and function at femtomolar concentrations [14]. In
HepG2 cells, regulation of acute-phase proteins by TGF-L1
has been demonstrated [15].
In rats, SeP levels have been correlated with protection
against free-radical-induced liver necrosis [16]. In human plas-
ma, SeP is e¡ective at preventing both oxidation and nitration
reactions mediated by peroxynitrite, a reactive oxygen species
Fig. 3. E¡ect of ActD on the TGF-L1-mediated inhibition of SeP
mRNA expression. Top: Cells were treated simultaneously with
TGF-L1 and ActD (lanes 1^5) or preincubated with TGF-L1 for 3 h
before addition of ActD (lanes 6^11). Bottom: Band intensities
from lanes 1^5 were normalized to GAPDH expression and shown
as relative expression to the untreated cells (0 h). Means of two in-
dependent experiments are given.
Fig. 4. SeP promoter activity in HepG2 cells after TGF-L1 treat-
ment. Cells were transfected with pGL3basic (open circles) or
BK4GL3 (closed squares). Values normalized for L-galactosidase ac-
tivity represent means þ S.E.M. in percent of controls, of three to
four independent experiments, each run in duplicate or triplicate.
Values not sharing a common letter are signi¢cantly di¡erent from
each other (P6 0.01, data shown for BK4GL3 only).
Table 1
Primer sequences and PCR conditions
Gene Sequence (5PC3P) Annealing temperature (‡C) Number of cycles Ref.
SeP FP: CAT CAG CAC CTT GGC AGC AGT 61 18 [2]
RP: CAA CTG GCA CTG GCT TCT GTG
GAPDH FP: TGA AGG TCG GAG TCA ACG GAT TTG GT 61 18 [25]
RP: CAT GTG GGC CAT GAG GTC CAC CAC
GPX3 FP: TAC ATC TGA CCG CCT CTT CTG 60 23 [26]
RP: CAC ACA CAC AAT CAC GCA TAC
GPX4 FP: CGC TGC TCT GTG GGG CTC TGG 60 23 [27]
RP: ACG CTG GAT TTT CGG GTC TGC
FP: forward primer; RP: reverse primer.
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endogenously formed by endothelial cells, activated macro-
phages and other cells involved in in£ammatory processes
[7]. SeP has been shown to bind to cellular membranes [17]
and associates with endothelial cells in rat tissues [18]. Hence,
SeP might act as an endothelial protection factor by inactivat-
ing peroxynitrite generated under pathological conditions, e.g.
acute lung injury, sepsis, and atherosclerosis [19^21]. Because
endothelial cells as well as macrophages and neutrophils do
not express SeP (V. Mostert, unpublished observation), there
is a necessity for SeP to be secreted in an endocrine fashion by
other cell types, e.g. hepatocytes, in which SeP expression is
high [22].
The inhibitory e¡ect of TGF-L1 on the expression of the
SeP gene is probably not an immediate one since de novo
synthesis of proteins as well as of mRNA is necessary for
downregulation of SeP expression. Consequently, TGF-L1
seems to induce the transcription and synthesis of one or
several factors which inhibit SeP transcription. The only tran-
scriptional partners for transduction of TGF-L signals identi-
¢ed so far are the Smad proteins [23]. The motif CAGACA
which has been shown to act as a Smad binding element in the
JunB promoter is present at position 31797 in the SeP pro-
moter [8]. A likely mechanism of Smad proteins inhibiting the
transcription of the SeP gene would be an obstruction of a
binding site for a basal transcription factor.
Our data represent the ¢rst observation of SeP regulation
by an endogenous mediator. TGF-L1 often counteracts the
induction of target genes by in£ammatory cytokines [24]. Fur-
ther experiments in cell and animal models will further eluci-
date a possible induction of SeP during in£ammation.
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